Connect with us
Prague Gaming & TECH Summit 2024

Artificial Intelligence

Global Large Volume Wearable Injectors Market Outlook to 2030 with Competitive Analysis on 400+ Players

Published

on

Dublin, July 24, 2020 (GLOBE NEWSWIRE) — The “Large Volume Wearable Injectors Market (5th Edition), 2020-2030: Focus on Bolus, Basal and Continuous Delivery Devices” report has been added to ResearchAndMarkets.com’s offering.One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities for large volume wearable injectors. Based on parameters, such as the number of commercialized devices, number of devices under development, price of the device and the annual adoption rate, we have provided an informed estimate on the likely evolution of the market over the period 2020-2030.The report also features sales forecasts for the overall large volume wearable injectors market with a detailed market segmentation on the:[A] type of device (patch pump, injector and infusion pump and injector)[B] usability (reusable and disposable)[C] therapeutic area (neurological disorders, cardiovascular disorders, infectious disease, oncological disorders and others)[D] key geographies (North America, Europe, Asia Pacific and rest of the world)Chronic diseases, such as diabetes, cardiovascular disorders, neurological disorders, autoimmune disorders and various types of cancer, are known to be the leading causes of death and disability across the world. The clinical conditions associated with these diseases affect patients’ overall quality of life. In fact, according to the World Health Organization (WHO), over 50% of the global population is currently estimated to be suffering from at least one chronic disease.The past few years have witnessed introduction of several innovative pharmaceutical interventions for the treatment of a number of such diseases. However, majority of the available treatment options require parenteral administration of the drug, frequent dosing, and involve repeated hospital visits.In fact, these drug delivery devices can prove to be potential vehicles for drug administration in disease outbreaks/pandemics (such as the one being faced due to the novel corona virus/COVID-19). Amongst modern drug delivery practices, the concept of self-injection has facilitated the administration of medications outside the clinical setting. Such practices also allow reductions in healthcare costs and enable the optimal usage of healthcare resources.The field is presently witnessing a lot of innovation, such as the development of integrated mobile applications with smart health monitoring, artificial intelligence algorithms and other interesting features (including provisions for reminders, and the ability to connect to web-based portals for sharing medical data with the concerned healthcare providers), visual/audible drug delivery confirmation notifications, automatic drug reconstitution, and error alerts. We believe that such efforts are likely to drive growth in this market over the coming years.An overview of current market landscape of the large volume wearable injectors available for delivery of insulin and non-insulin drugs, providing information on status of development and device specifications, such as type of device (patch pump/injector and infusion pump/injector), type of dose administered (basal, bolus and others), route of administration (subcutaneous and others), mode of injection (needle, needle/cannula and needle/catheter), storage capacity of the device, actuation mechanism (electromechanical, rotary pump, cell/expanded battery, pressurized gas, osmotic pressure and others), usability (disposable and reusable), availability of prefilled drug reservoir and availability of device connectivity. The report also features additional information on availability of prefilled insulin cartridges, availability of continuous glucose monitoring/blood glucose monitoring (CGM/BGM) systems, availability of Automated Insulin Delivery feature and type of remote control features (control within device/personal diabetes manager (PDM)/smartphone) in the insulin delivery devices.A detailed competitiveness analysis of large volume wearable injectors based on various relevant parameters, such as supplier power (based on the experience/expertise of the developer) and product specifications (type of device, type of dose, storage capacity of the device, usability, route of administration, connectivity and availability of a continuous glucose monitoring/blood glucose monitoring (CGM/BGM) systems (in case of insulin devices).Elaborate profiles of the prominent companies that develop large volume wearable injectors. Each company profile features a brief overview of the company, its financial information (if available), information on its product portfolio, recent developments and an informed future outlook. Additionally, the report includes tabulated profiles of wearable drug device combination products.An analysis of the partnerships that have been inked by the stakeholders in this domain, during the period between 2015 and 2020, covering acquisitions, product development agreements, product integration agreements, technology integration agreements, distribution and supply agreements, commercialization agreements, clinical trial agreements, licensing agreements, manufacturing agreements, service agreements, and other relevant types of deals.A detailed analysis on acquisition targets, taking into consideration the historical trend of the activity of the companies that have acquired other firms since 2000, and offering a means for other industry stakeholders to identify potential acquisition targets.An in-depth analysis of the various patents that have been submitted/filed related to large volume wearable injectors over the last three decades. It also highlights the key parameters associated with the patents, including information on patent type, issuing authority/patent offices involved, Cooperative Patent Classification (CPC) symbols, emerging areas (in terms of number of patents filed/granted), company type and leading industry, non-industry and individual patent assignees (in terms of size of intellectual property portfolio).A list of marketed drugs/therapies and pipeline candidates that are likely to be developed in combination with large volume wearable injectors in the near future, identified on the basis of an in-depth analysis of potential candidates, taking into consideration multiple parameters, such as stage of development, dosage, dose concentration, route of administration, type of dose and drug sales (in case of marketed drugs).A social media analysis depicting prevalent and emerging trends, and the popularity of large volume wearable injectors, as observed on the social media platform, Twitter. The analysis was based on tweets posted on the platform in the last few years.A detailed analysis of completed, ongoing and planned clinical trials of various large volume wearable injector products based on the various relevant parameters, such as trial registration year, current trial phase, trial status, study design, study focus, targeted therapeutic area and clinical outcomes.A case study on the role of contract manufacturing organizations in the overall manufacturing process/supply chain of wearable injectors. It includes information on the services provided by contract service providers for manufacturing of various device components (primary containers), infusion sets, adhesives, closures and injection moldings.An elaborate discussion on the various guidelines established by major regulatory bodies for medical device approval across North America (the US, Canada and Mexico), Europe (the UK, France, Germany, Italy, Spain and rest of Europe), Asia-Pacific and rest of the world (Australia, Brazil, China, India, Israel, Japan, New Zealand, Singapore, South Africa, South Korea, Taiwan, and Thailand). The report also features an insightful multi-dimensional, heat map analysis, featuring a comparison of the contemporary regulatory and reimbursement scenarios in key geographies across the globe.In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.Mark Banister (CEO, Medipacs/RxActuator)Michael Hooven (CEO, Enable Injections)Jesper Roested (CEO, Subcuject)Pieter Muntendam (former President and CEO, scPharmaceuticals)Menachem Zucker (VP and Chief Scientist, Elcam Medical)Graham Reynolds (VP and GM, Biologics, West Pharmaceutical Services)Mindy Katz (Director of Product, Sorrel Medical)
Key Questions AnsweredWho are the leading large volume wearable device developers?What are the prevalent trends within the competitive landscape of large volume wearable injectors for delivery of non-insulin drugs?What are the prevalent trends within the competitive landscape of large volume wearable injectors for delivery of insulin?What are the types of drug candidates that are suited for delivery via large volume wearable injectors?Who are the key contract service providers involved in this domain?What are medical device regulations across different regions?How is the current and future market opportunity likely to be distributed across key market segments?Key Topics Covered
1. Preface
2. Executive Summary
3. Introduction
4. Large Volume Wearable Injectors: Current Market Landscape
5. Product Competitiveness Analysis
6. Large Volume Wearable Injectors: Key Players
7. Drug-Device Combinations: Tabulated Profiles
8. Partnerships and Collaborations
9. Key Acquisition Targets
10. Patent Analysis
11. Large Volume Wearable Injectors: Likely Drug Candidates
12. Emerging Trends on Social Media
13. Clinical Trial Analysis
14. Case Study: Role of CMOs in Device Development Supply Chain
15. Regulatory and Reimbursement Landscape for Medical Devices
16. Market Sizing and Opportunity Analysis
17. SWOT Analysis
18. Executive Insights
Companies Mentioned
3MAbbottAbbVieAbGenomicsAblynxAcceleron PharmaAccentureActavis PharmaADC TherapeuticsAdrenomedAduro BiotechAdvaxisAeglea BioTherapeuticsAetnaAffibodyAffimedAgenusAgonOxAkesobio AustraliaAlder BioPharmaceuticalsAlectorAlexion PharmaceuticalsAlkahestAlkermesAllakosAllerganAlnylam PharmaceuticalsAllozyneAlphaCore PharmaAltor BioScienceAmbrxamcureAmgenAmicus TherapeuticsAmphivena TherapeuticsAmplyx PharmaceuticalsAngiochemAntares PharmaAntaros MedicalApellis PharmaceuticalsAprea TherapeuticsAptevo TherapeuticsargenxArgos TherapeuticsArmaGenARMO BioSciencesAronoraAsante SolutionsAscensia Diabetes CareAsklepion PharmaceuticalsAstorg PartnersAstellas PharmaAstraZenecaAtridiaAustralasian Medical & ScientificAxon NeuroscienceBarilBasilea PharmaceuticaBastian SolutionsBattelleBaxter InternationalBayerBayhill TherapeuticsBecton DickinsonBeiGeneBeijing Dongfang BiotechBespakBeta BionicsBigfoot BiomedicalBioArcticBIOCADBiogenBioIntegratorBioject Medical TechnologiesBioMarin PharmaceuticalBioniz TherapeuticsBioNTechBio-Path HoldingsBiotest PharmaceuticalsBio-Thera SolutionsBoehringer IngelheimBoston PharmaceuticalsBristol Myers SquibbBhler MotorCalando PharmaceuticalsCalibra MedicalCam MedCANbridge Life SciencesCancer AdvancesCara TherapeuticsCardiome PharmaCare InnovationsCatalyst BiosciencesCelgeneCelldex TherapeuticsCEL-SCICeQurChimerixCHO PharmaChugai PharmaceuticalCleveland BioLabsConjupro BiotherapeuticsConsort MedicalContraFectConvaTecCordant GroupCour Pharmaceutical DevelopmentCSL BehringCStone PharmaceuticalsCureTechCytoDynDaikyo SeikoDatwylerDebiotechDEKADekkunDelta-Fly PharmaDendreonDexcomDiabeloopDiaMedica TherapeuticsDiamyd MedicalDreaMed DiabetesDuke UniversityE3D Elcam Drug Delivery DevicesEuropean Connected Health Alliance (ECHAlliance)EG-GILEROEisaiEitan GroupEli LillyElusys TherapeuticsEMD SeronoEmergent BioSolutionsEnable InjectionsEndocyteEnGeneICEOFlowEpicentRxEris LifesciencesEVER PharmaEvidation HealthF2GFabricoFerring PharmaceuticalsFibroGenFitbitFive Prime TherapeuticsFlex PharmaFlexFlowonix MedicalFresenius Medical CareGalaxy BiotechGalena BiopharmaFedEx Supply ChainGenentechGENERONGeneScience PharmaceuticalsGenexineGenzymeGeorgia Institute of TechnologyGerresheimerGilead SciencesGlaxoSmithKlineGlenmark PharmaceuticalsGliknikGlookoGuangzhou Cellprotek PharmaceuticalHAL AllergyHalozyme TherapeuticsHanmi PharmaceuticalHarvard Pilgrim Health CareHaselmeierHealthPrize TechnologiesHelsinn HealthcareHemispherx BiopharmHoffmann-La RocheHuabo BiopharmIBM WatsonInternational Diabetes FederationImClone SystemsImmatics BiotechnologiesImmune Response BioPharmaImmunGeneImmunocoreImmunoFrontierImmunoGenImmunomedicsImmunotopeImmunovaccineImplicit BioscienceIncuronIncyteInnate PharmaInnovent BiologicsInovio PharmaceuticalsInsuletiNtRON BiotechnologyIO BiotechIonis PharmaceuticalsIpseniSense CGMISU ABXISJanssenJeriniJHL BiotechJiangsu Hengrui MedicineJiangsu T-Mab BiopharmaJohnson & JohnsonJounce TherapeuticsJuvenile Diabetes Research FoundationKaloBios PharmaceuticalsKiniksa PharmaceuticalsKissei PharmaceuticalKlueKura OncologyKyowa Hakko KirinLabrys BiologicsLEO PharmaLeviceptLife Science PharmaceuticalsMabVax TherapeuticsMacroGenicsMassachusetts Institute of TechnologyMedImmuneMedimop Medical ProjectsMedipacsMedtronicMedtrum TechnologiesMenarini DiagnosticsMenarini GroupMerckMerck Sharp & DohmeMercy Technology ServicesMereo BioPharmaMerrimack PharmaceuticalsMersana TherapeuticsMerusMerz PharmaMillennium PharmaceuticalsMiNA TherapeuticsmiRagen TherapeuticsMitsubishi Tanabe PharmaMode AGC (Automated Glucose Control)Moderna TherapeuticsMolecular PartnersMolecular TemplatesMolMedMontagu Private EquityMorphoSysMorphotekMoviMTD Micro MoldingmySugrNanoPass TechnologiesNantBioScienceNaurexNavidea BiopharmaceuticalsNemeraNeogenix OncologyNeon TherapeuticsNeuroDermNew Zealand Medical & ScientificNobleNordic BioscienceNordic InfucareNorthern BiologicsNovartis PharmaceuticalsNovimmuneNOVO EngineeringNovo NordiskOBI PharmaOctapharmaOmerosOncology VentureOncoMed PharmaceuticalsOncoPepOncopeptidesOncternal TherapeuticsOncuriousOptheaOptimer PharmaceuticalsOSE ImmunotherapeuticsOtsuka PharmaceuticalOwen MumfordPaion UKPanacea BiotecPercuSensePfizerPharmaJetPharmaMarPharmaSensPhaseBio PharmaceuticalsPhillips-MedisizePhilogenPhosplatin TherapeuticsPierre FabrePique TherapeuticsPolaris GroupPolyphorPrescient TherapeuticsPrestige BioPharmaPromediorPrometheus LaboratoriesProtalix BiotherapeuticsProven Process Medical DevicesPulmonary Hypertension AssociationQualcommQuest PharmaTechQuintessence BiosciencesRatio Drug DeliveryRAUMEDICRecro PharmaRecipharmRegeneron PharmaceuticalsREM SystemsREMD BiotherapeuticsResolve TherapeuticsrEVO BiologicsRhythm PharmaceuticalsRocheRoehr pharmaceuticalsR-PharmRubin MedicalRxActuatorSagentiaSamsung BioepisSandozSanofiSantarusSaol TherapeuticsSavient PharmaceuticalsscPharmaceuticalsSeattle GeneticsSelecta BiosciencesSelexys PharmaceuticalsSensile MedicalSerina TherapeuticsSFC FluidicsShireSHL MedicalSingularity UniversitySMC GlobalSmiths MedicalSoncebozSOOIL DevelopmentSPARK Strategic IdeasSQ InnovationSteadyMed TherapeuticsStealth BioTherapeuticsStemline TherapeuticsStevanato GroupSubcujectSumitomo Dainippon PharmaSunovion PharmaceuticalsSwissfillonSymBio PharmaceuticalsSymphogenSynecticsSynermore BiologicsSyntimmuneSyros PharmaceuticalsTaiMed BiologicsTaiwan Liposome CompanyTakeda PharmaceuticalTandem Diabetes CareTanvex BioPharmaTarveda TherapeuticsTeva PharmaceuticalTG TherapeuticsTheras LifetechTidepoolTolero PharmaceuticalsTRACON PharmaceuticalsTranslational SciencesTurnstone BiologicsTyndall National InstituteTypeZero TechnologiesUnion Chimique Belge (UCB)United BioPharmaUnited TherapeuticsUniversity of ArizonaUniversity of BernUniversity of ColoradoUniversity of HertfordshireUniversity of VirginiaVaccinexVaccinogenValtronicvasopharm BIOTECHVerily Life SciencesVetter PharmaViCentraViiV HealthcareVisterraVivozonWeibel CDSWest Pharmaceutical ServicesWockhardtXBiotechXencorXOMAYpsomedZafgenZealand PharmaZollnerZuellig PharmaFor more information about this report visit https://www.researchandmarkets.com/r/p6d8miResearch and Markets also offers Custom Research services providing focused, comprehensive and tailored research.CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

TRON Forum collaborates with four major microcontroller manufacturers to hold TRON Programming Contest Using World-Standard Real-Time OS with 5 million JP YEN cash prize

Published

on

tron-forum-collaborates-with-four-major-microcontroller-manufacturers-to-hold-tron-programming-contest-using-world-standard-real-time-os-with-5-million-jp-yen-cash-prize

TOKYO, March 29, 2024 /PRNewswire/ — TRON Forum (Chair: Ken Sakamura, Professor Emeritus of the University of Tokyo) is pleased to announce that four microcontroller manufacturers, Infineon Technologies Japan K.K. (President & CEO: Ikuya Kawasaki), STMicroelectronics K.K. (Country Manager for Japan: Koichiro Takakuwa), NXP Japan K.K. (President & CEO: Masayuki Wajima), and Renesas Electronics Corporation (President & CEO: Hidetoshi Shibata) have collaborated with the Forum to hold TRON Programming Contest from Monday, December 11, 2023 jointly. The initial registration is being accepted now.

This contest is for engineers and students in Japan and overseas to compete in various  fields such as microcontroller applications, middleware, development environments, and tools using a member of TRON real-time OS (RTOS) family, “μT-Kernel 3.0” (*), which is a global standard of small-scale embedded computer systems.
(*) μT-Kernel 3.0 is an RTOS that fully complies with the real-time OS standard “IEEE 2050-2018” (IEEE Standard for a Real-Time Operating System (RTOS) for Small-Scale Embedded Systems) and runs on microcontrollers from various manufacturers.
Using the latest microcomputer boards provided by the manufacturers, contestants will compete in technologies that bring out the characteristics of RTOSs such as real-time performance, power saving, and small memory footprint, as well as development environments and tools that utilize new technologies.
The details of the contest with the total amount of cash prize, five million Japanese yen are at the following URL: https://www.tron.org/programming_contest/
About TRON Forum
TRON Forum was established in 2002 to promote TRON Project. We have been actively conducting activities centered on the T-Engine project, which prepares the development environment for embedded systems, and the operation of Ubiquitous ID Centers such as ucode.
In May 2015, Chair Sakamura received the ITU 150th Anniversary Award together with Bill Gates and others for his advocacy of open architecture TRON, which is the origin of ubiquitous networking and the IoT.
One member of the TRON RTOS family has been adopted as an international standard for real-time operating systems (RTOS) for small-scale embedded systems as 2050-2018 by Institute of Electrical and Electronics Engineers (IEEE), the world’s largest association of its kind and an international standardization organization. In 2023, the project leader, Chair Sakamura, received the IEEE Masaru Ibuka Consumer Technology Award from the IEEE in honor of the late Mr. Ibuka. In addition, the TRON RTOS family received the IEEE Milestone recognition in 2023.
URL: https://www.tron.org 
 
 

View original content:https://www.prnewswire.co.uk/news-releases/tron-forum-collaborates-with-four-major-microcontroller-manufacturers-to-hold-tron-programming-contest-using-world-standard-real-time-os-with-5-million-jp-yen-cash-prize-302103284.html

Continue Reading

Artificial Intelligence

XtalPi Unveils XtalGazer: A Comprehensive AI-Driven Polymorph Selection Platform

Published

on

xtalpi-unveils-xtalgazer:-a-comprehensive-ai-driven-polymorph-selection-platform

CAMBRIDGE, Mass., March 28, 2024 /PRNewswire/ — XtalPi Inc., a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of groundbreaking medicine and innovative materials, announced today the launch of its proprietary comprehensive solid form discovery and selection platform, XtalGazer. This advanced platform aims to significantly improve the polymorph selection process for the pharmaceutical industry by integrating AI- and automation-powered experimental and computational approaches.

XtalGazer provides a total solution for delivering high-quality polymorph screening and selection methods to expedite drug development and mitigate risks. It represents a paradigm shift in solid-state research, moving from the traditional trial-and-error approach to a data-driven, design-led methodology. The platform provides an expansive suite of foundational tools to accelerate polymorph discovery, characterization, and selection process, empowering pharmaceutical companies to conduct thorough research with less active pharmaceutical ingredient (API) in shorter development cycles.
A key component of XtalGazer is XtalCSP, a crystal structure prediction platform to perform global searches of crystal structures for target molecules and the other optional components in the corresponding searching space, offering a deep insight into possible stable forms. Furthermore, crystallization strategy recommendations will provide AI-backed experimental design to help avoid human bias. XtalGazer also utilizes MicroED to rapidly elucidate crystal structures from powder samples, reducing the need for growing single crystals.
XtalPi’s launch of XtalGazer marks another significant step in the company’s ongoing exploration of solid-state research. From crystal structure prediction platforms being one of the first products to launch at XtalPi, to today’s comprehensive polymorph selection platform, XtalPi will keep fulfilling its promise to solving challenging problems in this space. XtalPi will continue to deliver faster, more accurate, and more comprehensive approaches to building an ecosystem for the R&D process in solid-state, pre-formulation and crystallization.
For more information about XtalPi, please visit www.xtalpi.com.
About XtalPi:
XtalPi is an innovative technology company powered by artificial intelligence (AI) and robotics. Founded in 2015 on the MIT campus, XtalPi is dedicated to driving intelligent and digital transformation in the life science and new materials industries. With tightly interwoven quantum physics, AI, cloud computing, and large-scale clusters of robotic workstations, XtalPi offers a range of technology solutions, services, and products to accelerate and empower innovation for biopharmaceutical and new materials companies worldwide.
Media Contact: Vivienne [email protected]
Logo – https://mma.prnewswire.com/media/632519/XtalPi_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/xtalpi-unveils-xtalgazer-a-comprehensive-ai-driven-polymorph-selection-platform-302102794.html

Continue Reading

Artificial Intelligence

ICIS and Base Oil News Announce Partnership to Enhance Market Insights

Published

on

icis-and-base-oil-news-announce-partnership-to-enhance-market-insights

LONDON, March 28, 2024 /PRNewswire/ — ICIS, a global source of commodity intelligence, is pleased to announce a strategic partnership with Base Oil News, a premier news outlet founded by industry expert Iain Pocock that provides in-depth coverage of the base oils and lubricants market. This collaboration marks a significant milestone in the dissemination and exchange of critical market data and insights.

With more than two decades of journalism experience at Bloomberg, Reuters, and Argus Media, Iain Pocock brings unparalleled expertise to this partnership. His deep understanding of illiquid energy markets makes him a credible and influential figure in the industry. Since November 2023, Iain has been working closely with ICIS to share and exchange valuable data and insights, enhancing the services both platforms offer to the base oils and lubricants market.
Through the collaboration, Iain integrates ICIS’ extensive content and data resources in Base Oil News market coverage. In return, he contributes market insights to ICIS News, including expert and exclusive analysis of supply and demand dynamics, price margins, and other critical market drivers. This exchange ensures that subscribers of both ICIS and Base Oil News have access to the most comprehensive, timely, and accurate market information, empowering them to make informed decisions.
“It’s a very exciting partnership – where we leverage each other’s strengths and provide actionable insights to our customers,” said Iain Pocock, Founder of Base Oil News. “The market is the winner.”
“As ICIS is already the world’s most trusted pricing benchmark for base oils, this collaboration with Iain Pocock and Base Oil News provides an even stronger and deeper service to our customers,” said Stephen Burns, Editorial Director at ICIS. “Iain’s expertise and extensive industry connections are invaluable, and we have established a fruitful partnership that benefits the market at large.”
For the latest insights from Iain Pocock on ICIS News, visit ICIS News.  
About ICIS
ICIS – Independent Commodity Intelligence Services – helps businesses through seamlessly delivering data and analytics, across the chemical, fertilizer and energy markets. A trusted source and benchmark for price information and insight across key commodities markets worldwide. Our independent, transparent market intelligence informs thousands of quality decisions every day, taking the pressure out of negotiations and giving customers space for more innovative thinking, through published datasets including price assessments, price forecasts, supply and demand fundamentals and more.
Over 150 years of shaping the world by connecting markets to optimise the world’s valuable resources. With a global team of more than 600 experts, ICIS has employees based in London, New York, Houston, Karlsruhe, Milan, Mumbai, Singapore, Guangzhou, Beijing, Shanghai, Dubai, Sao Paulo, Seoul, Tokyo and Perth.
ICIS is part of RELX, a FTSE15 company with a market cap of £64bn and an employee base of over 30,000 experts across 40 countries.
About RELX
RELX is a global provider of information and analytics for professional and business customers across industries. The Group serves customers in more than 180 countries and has offices in about 40 countries. It employs approximately 30,000 people of whom almost half are in North America. RELX PLC is a London listed holding company which owns 52.9% of RELX Group. RELX NV is an Amsterdam listed holding company which owns 47.1% of RELX Group. The shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX and RENX. Total market capitalisation is approximately £64bn | €75bn | $81bn.
Logo: https://mma.prnewswire.com/media/619935/4277787/ICIS_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/icis-and-base-oil-news-announce-partnership-to-enhance-market-insights-302102782.html

Continue Reading
Advertisement

Latest News

Trending